Moderna raises 2026 revenue growth forecast to 15%–25% as quarterly profit returns
Moderna raised its 2026 revenue growth forecast to 15%–25%, from up to 10%, as strong international COVID-19 vaccine demand and partnership payments helped it return to profit in the third quarter. The company reported quarterly revenue of $1.3 billion and net profit of $162 million, compared with a net loss of about $200 million a year earlier.